CN101291927A - 可用作蛋白激酶抑制剂的苯并咪唑 - Google Patents
可用作蛋白激酶抑制剂的苯并咪唑 Download PDFInfo
- Publication number
- CN101291927A CN101291927A CNA2006800343024A CN200680034302A CN101291927A CN 101291927 A CN101291927 A CN 101291927A CN A2006800343024 A CNA2006800343024 A CN A2006800343024A CN 200680034302 A CN200680034302 A CN 200680034302A CN 101291927 A CN101291927 A CN 101291927A
- Authority
- CN
- China
- Prior art keywords
- compound
- independently
- group
- formula
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70239905P | 2005-07-26 | 2005-07-26 | |
| US60/702,399 | 2005-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101291927A true CN101291927A (zh) | 2008-10-22 |
Family
ID=37680602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006800343024A Pending CN101291927A (zh) | 2005-07-26 | 2006-07-21 | 可用作蛋白激酶抑制剂的苯并咪唑 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8076343B2 (https=) |
| EP (2) | EP2336122B1 (https=) |
| JP (2) | JP5255438B2 (https=) |
| KR (1) | KR20080034483A (https=) |
| CN (1) | CN101291927A (https=) |
| AT (1) | ATE484501T1 (https=) |
| AU (1) | AU2006276088A1 (https=) |
| CA (1) | CA2616159A1 (https=) |
| DE (1) | DE602006017574D1 (https=) |
| ES (1) | ES2351357T3 (https=) |
| IL (1) | IL188942A0 (https=) |
| NO (1) | NO20080967L (https=) |
| NZ (1) | NZ566021A (https=) |
| RU (1) | RU2415853C2 (https=) |
| TW (1) | TW200745088A (https=) |
| WO (1) | WO2007015923A2 (https=) |
| ZA (1) | ZA200800992B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112552287A (zh) * | 2020-12-16 | 2021-03-26 | 北京华氏开元医药科技有限公司 | 一种吲哚类衍生物药物制剂及其制备方法 |
| WO2023116888A1 (zh) * | 2021-12-23 | 2023-06-29 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105367503A (zh) | 2007-10-19 | 2016-03-02 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| US9336046B2 (en) | 2012-06-15 | 2016-05-10 | International Business Machines Corporation | Transaction abort processing |
| US9512136B2 (en) * | 2012-11-26 | 2016-12-06 | Universal Display Corporation | Organic electroluminescent materials and devices |
| EP2976336A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2014170421A1 (en) * | 2013-04-19 | 2014-10-23 | F. Hoffmann-La Roche Ag | Serine/threonine kinase inhibitors |
| ITUA20164278A1 (it) * | 2016-06-10 | 2017-12-10 | International Soc For Drug Development S R L | COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA |
| US10793551B2 (en) | 2017-10-19 | 2020-10-06 | Effector Therapeutics Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4535350B2 (ja) * | 1998-11-17 | 2010-09-01 | クミアイ化学工業株式会社 | ピリミジニルベンズイミダゾール誘導体及び農園芸用殺菌剤 |
| CN1243002C (zh) | 1998-11-17 | 2006-02-22 | 组合化学工业株式会社 | 嘧啶基苯并咪唑和三嗪基苯并咪唑衍生物及农业/园艺杀菌剂 |
| WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| EP1257546A1 (en) | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| EP1389617B1 (en) * | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| NZ537156A (en) * | 2002-05-23 | 2007-06-29 | Cytopia Pty Ltd | Kinase inhibitors |
| CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| NZ546058A (en) * | 2004-01-12 | 2010-09-30 | Ym Biosciences Australia Pty | Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors |
-
2006
- 2006-07-21 US US11/492,643 patent/US8076343B2/en not_active Expired - Fee Related
- 2006-07-21 ES ES06787944T patent/ES2351357T3/es active Active
- 2006-07-21 CN CNA2006800343024A patent/CN101291927A/zh active Pending
- 2006-07-21 WO PCT/US2006/028149 patent/WO2007015923A2/en not_active Ceased
- 2006-07-21 DE DE602006017574T patent/DE602006017574D1/de active Active
- 2006-07-21 AU AU2006276088A patent/AU2006276088A1/en not_active Abandoned
- 2006-07-21 ZA ZA200800992A patent/ZA200800992B/xx unknown
- 2006-07-21 EP EP10185388.5A patent/EP2336122B1/en not_active Not-in-force
- 2006-07-21 AT AT06787944T patent/ATE484501T1/de not_active IP Right Cessation
- 2006-07-21 JP JP2008523972A patent/JP5255438B2/ja not_active Expired - Fee Related
- 2006-07-21 NZ NZ566021A patent/NZ566021A/en not_active IP Right Cessation
- 2006-07-21 CA CA002616159A patent/CA2616159A1/en not_active Abandoned
- 2006-07-21 RU RU2008106949/04A patent/RU2415853C2/ru not_active IP Right Cessation
- 2006-07-21 EP EP06787944A patent/EP1937667B1/en not_active Not-in-force
- 2006-07-21 KR KR1020087004634A patent/KR20080034483A/ko not_active Ceased
- 2006-07-26 TW TW095127328A patent/TW200745088A/zh unknown
-
2008
- 2008-01-22 IL IL188942A patent/IL188942A0/en unknown
- 2008-02-26 NO NO20080967A patent/NO20080967L/no not_active Application Discontinuation
-
2013
- 2013-02-13 JP JP2013025417A patent/JP2013082757A/ja not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112552287A (zh) * | 2020-12-16 | 2021-03-26 | 北京华氏开元医药科技有限公司 | 一种吲哚类衍生物药物制剂及其制备方法 |
| CN112552287B (zh) * | 2020-12-16 | 2021-11-30 | 北京华氏精恒医药科技有限公司 | 一种吲哚类衍生物药物制剂及其制备方法 |
| WO2023116888A1 (zh) * | 2021-12-23 | 2023-06-29 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009502921A (ja) | 2009-01-29 |
| WO2007015923A8 (en) | 2008-04-03 |
| US20070099920A1 (en) | 2007-05-03 |
| NO20080967L (no) | 2008-04-22 |
| JP2013082757A (ja) | 2013-05-09 |
| NZ566021A (en) | 2011-03-31 |
| WO2007015923A2 (en) | 2007-02-08 |
| TW200745088A (en) | 2007-12-16 |
| ATE484501T1 (de) | 2010-10-15 |
| EP2336122B1 (en) | 2014-05-14 |
| DE602006017574D1 (de) | 2010-11-25 |
| US8076343B2 (en) | 2011-12-13 |
| AU2006276088A1 (en) | 2007-02-08 |
| WO2007015923A3 (en) | 2007-04-19 |
| ES2351357T3 (es) | 2011-02-03 |
| ZA200800992B (en) | 2009-09-30 |
| IL188942A0 (en) | 2008-04-13 |
| CA2616159A1 (en) | 2007-02-08 |
| KR20080034483A (ko) | 2008-04-21 |
| EP2336122A1 (en) | 2011-06-22 |
| EP1937667B1 (en) | 2010-10-13 |
| RU2415853C2 (ru) | 2011-04-10 |
| JP5255438B2 (ja) | 2013-08-07 |
| RU2008106949A (ru) | 2009-09-10 |
| EP1937667A2 (en) | 2008-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1562938B1 (en) | Heteroaryl-pyrimidine derivatives as jak inhibitors | |
| TWI501768B (zh) | 嗒酮衍生物 | |
| US7312227B2 (en) | Compositions useful as inhibitors of JAK and other protein kinases | |
| CN103124730B (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| JP2013082757A (ja) | プロテインキナーゼ阻害薬として有用なベンズイミダゾール | |
| CA2946130A1 (en) | Quinoxaline compounds and uses thereof | |
| AU2004215428A1 (en) | Aminoheteroaryl compounds as protein kinase inhibitors | |
| CN101687852A (zh) | 可用作激酶抑制剂的噻唑类和吡唑类化合物 | |
| CN101679378A (zh) | 用作激酶抑制剂的噻唑和吡唑 | |
| CA2942687A1 (en) | 5-substituted indazole-3-carboxamides and preparation and use thereof | |
| BRPI0720635A2 (pt) | Compostos orgânicos e seus usos | |
| CN101848909A (zh) | 可用作蛋白激酶抑制剂的吡咯并[3,2-c]吡啶 | |
| CN101801959A (zh) | 可用作激酶抑制剂的氨基嘧啶类化合物 | |
| CN101679387A (zh) | 可用作激酶抑制剂的氨基嘧啶类化合物 | |
| CN101679386A (zh) | 可用作激酶抑制剂的氨基嘧啶类化合物 | |
| CA2974078A1 (en) | Quinazoline and quinoline compounds and uses thereof | |
| ES2433469T3 (es) | Moduladores de la aurora cinasa y métodos de uso | |
| CA3147443A1 (en) | Compounds and method for treating cytokine release syndrome | |
| HK1122558A (en) | Benzimidazoles useful as inhibitors of protein kinases | |
| CN101273032A (zh) | 吡嗪激酶抑制剂 | |
| MX2008001172A (en) | Benzimidazoles useful as inhibitors of protein kinases | |
| HK1138587A (en) | Thiazoles and pyrazoles useful as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1122558 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20081022 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1122558 Country of ref document: HK |